



## Clinical trial results:

**A randomized, multi-center Phase IIIb, open label, study of letrozole vs anastrozole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer**

**Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please use <https://www.novctrd.com/CtrdWeb/home.novfor> complete trial results.**

## Summary

EudraCT number	2005-004263-35
Trial protocol	IE FI ES SE GB AT DK BE DE IT
Global end of trial date	08 September 2014

## Results information

Result version number	v1 (current)
This version publication date	06 July 2018
First version publication date	06 July 2018

## Trial information

### Trial identification

Sponsor protocol code	CFEM345D2411
-----------------------	--------------

### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00248170
WHO universal trial number (UTN)	-

Notes:

## Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111,
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111,

Notes:

## Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 September 2014
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	08 September 2014
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective was to compare the rate of disease-free survival (DFS) when 959 DFS events had occurred in postmenopausal women with hormone receptor and lymph node positive breast cancer randomized between letrozole and anastrozole.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 December 2005
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy
Long term follow-up duration	3 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 301
Country: Number of subjects enrolled	Austria: 198
Country: Number of subjects enrolled	Belgium: 139
Country: Number of subjects enrolled	Canada: 124
Country: Number of subjects enrolled	China: 38
Country: Number of subjects enrolled	Denmark: 270
Country: Number of subjects enrolled	Finland: 21
Country: Number of subjects enrolled	France: 206
Country: Number of subjects enrolled	Germany: 358
Country: Number of subjects enrolled	Ireland: 165
Country: Number of subjects enrolled	Israel: 103
Country: Number of subjects enrolled	Italy: 305
Country: Number of subjects enrolled	Japan: 297
Country: Number of subjects enrolled	Korea, Republic of: 30

Country: Number of subjects enrolled	Netherlands: 85
Country: Number of subjects enrolled	New Zealand: 65
Country: Number of subjects enrolled	Norway: 13
Country: Number of subjects enrolled	Spain: 104
Country: Number of subjects enrolled	Sweden: 59
Country: Number of subjects enrolled	Switzerland: 20
Country: Number of subjects enrolled	United Kingdom: 282
Country: Number of subjects enrolled	United States: 953
Worldwide total number of subjects	4136
EEA total number of subjects	2205

Notes:

---

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	2490
From 65 to 84 years	1646
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Participants, who had recently undergone surgery, were randomly assigned in 1:1 ratio to letrozole or anastrozole. Participants received daily treatment until disease recurrence/relapse or for a maximum of 5 years. Participants underwent post-treatment long term follow-up for disease-free survival and overall survival.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Letrozole
------------------	-----------

Arm description:

2.5 mg by mouth (p.o.) once daily

Arm type	Experimental
Investigational medicinal product name	Letrozole
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

2.5 mg orally once a day

<b>Arm title</b>	Anastrozole
------------------	-------------

Arm description:

1 mg p.o. once daily

Arm type	Active comparator
Investigational medicinal product name	Anastrozole
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

1 mg orally once a day

<b>Number of subjects in period 1</b>	Letrozole	Anastrozole
Started	2061	2075
Intent-to-treat (ITT)	2061	2075
Safety set	2049	2062
Completed	1317	1286
Not completed	744	789
Adverse event, serious fatal	28	47
Consent withdrawn by subject	71	79
Disease progression	196	216
Abnormal test procedure(s) result	49	61
Adverse event, non-fatal	311	296
Administrative problems	22	25
Abnormal laboratory values	4	-
Lost to follow-up	28	35
Protocol deviation	35	30

## Baseline characteristics

### Reporting groups

Reporting group title	Letrozole
Reporting group description: 2.5 mg by mouth (p.o.) once daily	
Reporting group title	Anastrozole
Reporting group description: 1 mg p.o. once daily	

Reporting group values	Letrozole	Anastrozole	Total
Number of subjects	2061	2075	4136
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	1236	1254	2490
From 65-84 years	806	802	1608
85 years and over	19	19	38
Age Continuous   Units: Years			
arithmetic mean	63.2	63.1	
standard deviation	± 8.48	± 8.45	-
Gender categorical Units: Subjects			
Female	2061	2075	4136
Male	0	0	0
Gender, Customized Units: Subjects			
Female	2061	2075	4136

## End points

### End points reporting groups

Reporting group title	Letrozole
Reporting group description: 2.5 mg by mouth (p.o.) once daily	
Reporting group title	Anastrozole
Reporting group description: 1 mg p.o. once daily	

### Primary: Disease free survival

End point title	Disease free survival
End point description: Disease-free survival was defined as the time from the date of randomization to the date of the first documentation of re-occurrence of invasive breast cancer in local, regional or distant sites, new invasive breast cancer in the contra-lateral breast, or death from any cause.	
End point type	Primary
End point timeframe: 84 months	

End point values	Letrozole	Anastrozole		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2061	2075		
Units: Months				
median (confidence interval)	999 (84.14 to 999)	999 (-999 to 999)		

### Statistical analyses

Statistical analysis title	Disease free survival
Comparison groups	Anastrozole v Letrozole
Number of subjects included in analysis	4136
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.315
Method	Logrank

### Secondary: Overall survival

End point title	Overall survival
End point description: Overall survival was defined as the time from the date of randomization to the date of death from any	

cause.

End point type	Secondary
End point timeframe:	
84 months	

End point values	Letrozole	Anastrozole		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2061	2075		
Units: Months				
median (confidence interval)	999 (-999 to 999)	999 (-999 to 999)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to development of distant metastases

End point title	Time to development of distant metastases
End point description:	
Time to development of distant metastases was defined as the time from date of randomization to the date of the first development of any recurrent or metastatic disease in sites other than the local mastectomy scar, the ipsilateral breast in case of breast conservation or the contra lateral breast.	
End point type	Secondary
End point timeframe:	
84 months	

End point values	Letrozole	Anastrozole		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2061	2075		
Units: Months				
median (confidence interval)	999 (84.14 to 999)	999 (-999 to 999)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to development of contra lateral breast cancer

End point title	Time to development of contra lateral breast cancer
End point description:	
Time to development of contra lateral breast cancer was defined as the time from the date of randomization to the date of the first development of any disease in the contra lateral breast.	



End point type	Secondary
End point timeframe:	
84 months	

End point values	Letrozole	Anastrozole		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2061	2075		
Units: Months				
median (confidence interval)	999 (-999 to 999)	999 (-999 to 999)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Distant disease-free survival

End point title	Distant disease-free survival
End point description:	
Distant disease-free survival was defined as the time from date of randomization to the date of the first development of any relapse at a distant site or death from any cause.	
End point type	Secondary
End point timeframe:	
84 months	

End point values	Letrozole	Anastrozole		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2061	2075		
Units: Months				
median (confidence interval)	999 (84.14 to 999)	999 (-999 to 999)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in serum lipid profiles

End point title	Change from baseline in serum lipid profiles
End point description:	
Total cholesterol was analyzed to assess the impact on serum lipids profiles. The adjusted means was calculated.	
End point type	Secondary

End point timeframe:  
baseline, 6, 12, 24, 36, 48 and 60 months

End point values	Letrozole	Anastrozole		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2049	2062		
Units: mg/dL				
arithmetic mean (confidence interval)				
6 months	5.643 (5.584 to 5.701)	5.553 (5.495 to 5.611)		
12 months	5.569 (5.51 to 5.629)	5.511 (5.452 to 5.57)		
24 months	5.508 (5.445 to 5.572)	5.436 (5.373 to 5.499)		
36 months	5.429 (5.359 to 5.5)	5.427 (5.357 to 5.497)		
48 months	5.395 (5.323 to 5.468)	5.366 (5.293 to 5.438)		
60 months	5.375 (5.3 to 5.451)	5.368 (5.292 to 5.443)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of participants who experienced clinical fracture events

End point title	Percentage of participants who experienced clinical fracture events
-----------------	---

End point description:

The incidence of clinical fractures was analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

84 months

End point values	Letrozole	Anastrozole		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2049	2062		
Units: Percentage of participants				
number (not applicable)	9.3	8.1		

### Statistical analyses

No statistical analyses for this end point

---

**Secondary: Percentage of participants who experienced cardiovascular events**

---

End point title	Percentage of participants who experienced cardiovascular events
-----------------	--

End point description:

The incidence of ischemic heart disease, cardiac failures, cerebrovascular accidents and thromboembolic events was analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

84 months

---

End point values	Letrozole	Anastrozole		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2049	2062		
Units: Percentage of participants				
number (not applicable)				
Ischemic heart disease	2.4	1.5		
Cardiac failures	1.5	0.7		
Cerebrovascular accidents	1.6	1.5		
Thromboembolic events	1.2	1.2		

---

**Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.

Adverse event reporting additional description:

Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events field "number of deaths resulting from adverse events" all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	17.0

### Reporting groups

Reporting group title	Anastrozole
-----------------------	-------------

Reporting group description:

Anastrozole

Reporting group title	Letrozole
-----------------------	-----------

Reporting group description:

Letrozole

Serious adverse events	Anastrozole	Letrozole	
Total subjects affected by serious adverse events			
subjects affected / exposed	520 / 2062 (25.22%)	485 / 2049 (23.67%)	
number of deaths (all causes)	46	42	
number of deaths resulting from adverse events	2	1	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma of the cervix			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiomyolipoma			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-cell lymphoma			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign laryngeal neoplasm			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign lymph node neoplasm			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of thyroid gland			
subjects affected / exposed	3 / 2062 (0.15%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign salivary gland neoplasm			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone cancer			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain neoplasm			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Breast cancer			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon neoplasm			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diffuse large B-cell lymphoma			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibroma			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibromatosis			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder cancer			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cancer			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal carcinoma			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastrointestinal tract adenoma			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma multiforme			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemangioma			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cancer			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lip and/or oral cavity cancer			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lip neoplasm benign			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lymphangiosis carcinomatosa			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma in situ			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm progression			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant peritoneal neoplasm			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant pleural effusion			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma			



subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to abdominal cavity			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to bone			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to central nervous system			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to liver			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastases to peritoneum			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastatic pain			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurilemmoma benign			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Ovarian cancer			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer stage III			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Ovarian fibroma			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian neoplasm			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pituitary tumour benign			
subjects affected / exposed	2 / 2062 (0.10%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleomorphic adenoma			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal adenoma			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectosigmoid cancer			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Retro-orbital neoplasm			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland neoplasm			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Schwannoma			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seborrhoeic keratosis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Signet-ring cell carcinoma			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Squamous cell carcinoma			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of skin			

subjects affected / exposed	4 / 2062 (0.19%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superficial spreading melanoma stage unspecified			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid adenoma			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid neoplasm			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine leiomyoma			
subjects affected / exposed	1 / 2062 (0.05%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Waldenstrom's macroglobulinaemia			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Aortic aneurysm			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Aortic aneurysm rupture			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Aortic dissection			

subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Aortic stenosis			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic thrombosis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial disorder			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial occlusive disease			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Capillary fragility			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circulatory collapse			
subjects affected / exposed	4 / 2062 (0.19%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Deep vein thrombosis			

subjects affected / exposed	8 / 2062 (0.39%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	2 / 8	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extremity necrosis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral artery occlusion			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	2 / 2062 (0.10%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	4 / 2062 (0.19%)	7 / 2049 (0.34%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	0 / 2062 (0.00%)	4 / 2049 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			

subjects affected / exposed	1 / 2062 (0.05%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hypovolaemic shock			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iliac artery occlusion			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-abdominal haematoma			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphocele			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoedema			
subjects affected / exposed	3 / 2062 (0.15%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral vascular disorder			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral venous disease			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Temporal arteritis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thromboangiitis obliterans			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose vein			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vena cava thrombosis			



subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis limb			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Breast lump removal			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast operation			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast prosthesis implantation			
subjects affected / exposed	10 / 2062 (0.48%)	5 / 2049 (0.24%)	
occurrences causally related to treatment / all	0 / 14	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast prosthesis removal			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast reconstruction			
subjects affected / exposed	16 / 2062 (0.78%)	24 / 2049 (1.17%)	
occurrences causally related to treatment / all	0 / 18	0 / 27	
deaths causally related to treatment / all	0 / 0	0 / 0	
Central venous catheter removal			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee arthroplasty			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mammoplasty			
subjects affected / exposed	3 / 2062 (0.15%)	6 / 2049 (0.29%)	
occurrences causally related to treatment / all	0 / 3	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mastectomy			
subjects affected / exposed	6 / 2062 (0.29%)	5 / 2049 (0.24%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mechanical ventilation			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device removal			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus removal			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Modified radical mastectomy			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Removal of internal fixation			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scar excision			

subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal laminectomy			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound treatment			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	6 / 2062 (0.29%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	1 / 6	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac death			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Chest discomfort			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	2 / 2062 (0.10%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
Device damage			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device dislocation			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device malfunction			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disease progression			
subjects affected / exposed	2 / 2062 (0.10%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disease recurrence			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drowning			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Fat necrosis			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	2 / 2062 (0.10%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gait disturbance			

subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	3 / 2062 (0.15%)	4 / 2049 (0.20%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site extravasation			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injection site phlebitis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			
subjects affected / exposed	3 / 2062 (0.15%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	1 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multi-organ failure			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Non-cardiac chest pain			
subjects affected / exposed	2 / 2062 (0.10%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patient-device incompatibility			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	8 / 2062 (0.39%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 8	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden death			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Thrombosis in device			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic shock			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug hypersensitivity			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypersensitivity			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sarcoidosis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Adnexa uteri mass			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anisomastia			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast calcifications			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast haematoma			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast fibrosis			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast inflammation			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast mass			

subjects affected / exposed	2 / 2062 (0.10%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast oedema			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colpocoele			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystocele			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial hyperplasia			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Female genital tract fistula			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Genital prolapse			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metrorrhagia			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nipple disorder			



subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nipple exudate bloody			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cyst			
subjects affected / exposed	3 / 2062 (0.15%)	5 / 2049 (0.24%)	
occurrences causally related to treatment / all	1 / 3	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic prolapse			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perineal pain			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectocele			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine fistula			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Uterine polyp			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine prolapse			

subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal haemorrhage			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal inflammation			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal prolapse			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspiration			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma			
subjects affected / exposed	3 / 2062 (0.15%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial hyperreactivity			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchospasm			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Choking			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Chronic obstructive pulmonary disease			
subjects affected / exposed	9 / 2062 (0.44%)	6 / 2049 (0.29%)	
occurrences causally related to treatment / all	0 / 10	0 / 6	
deaths causally related to treatment / all	0 / 4	0 / 0	
Dyspnoea			
subjects affected / exposed	7 / 2062 (0.34%)	10 / 2049 (0.49%)	
occurrences causally related to treatment / all	0 / 7	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea exertional			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Emphysema			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			

subjects affected / exposed	2 / 2062 (0.10%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercapnia			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypoxia			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Idiopathic pulmonary fibrosis			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Pleural effusion			
subjects affected / exposed	3 / 2062 (0.15%)	5 / 2049 (0.24%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleuritic pain			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	3 / 2062 (0.15%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Productive cough			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	12 / 2062 (0.58%)	6 / 2049 (0.29%)	
occurrences causally related to treatment / all	4 / 12	1 / 6	
deaths causally related to treatment / all	0 / 1	0 / 1	
Pulmonary fibrosis			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hypertension			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Respiratory failure			
subjects affected / exposed	3 / 2062 (0.15%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 2	
Sinus congestion			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sleep apnoea syndrome			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Abnormal behaviour			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Agitation			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Completed suicide			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Confusional state			
subjects affected / exposed	8 / 2062 (0.39%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 8	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depressed mood			
subjects affected / exposed	3 / 2062 (0.15%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			

subjects affected / exposed	11 / 2062 (0.53%)	9 / 2049 (0.44%)	
occurrences causally related to treatment / all	1 / 14	1 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug dependence			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intentional self-injury			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Major depression			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental disorder			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
subjects affected / exposed	2 / 2062 (0.10%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mood disorder due to a general medical condition			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mood swings			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Somatisation disorder			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Amylase increased			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspiration pleural cavity			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy breast			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy lymph gland			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone density decreased			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carbohydrate antigen 15-3 increased			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium test positive			



subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibrin D dimer increased			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoglobin decreased			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
International normalised ratio increased			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipase increased			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mammogram abnormal			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mediastinal biopsy			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight decreased			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight increased			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Acetabulum fracture			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol poisoning			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			
subjects affected / exposed	10 / 2062 (0.48%)	14 / 2049 (0.68%)	
occurrences causally related to treatment / all	1 / 10	5 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthropod bite			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain contusion			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical vertebral fracture			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clavicle fracture			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Compression fracture			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dislocation of vertebra			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Excoriation			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Face injury			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture			
subjects affected / exposed	2 / 2062 (0.10%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	13 / 2062 (0.63%)	17 / 2049 (0.83%)	
occurrences causally related to treatment / all	0 / 13	1 / 17	
deaths causally related to treatment / all	0 / 0	0 / 1	
Femoral neck fracture			

subjects affected / exposed	3 / 2062 (0.15%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	1 / 3	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	2 / 2062 (0.10%)	8 / 2049 (0.39%)	
occurrences causally related to treatment / all	0 / 2	1 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibula fracture			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			
subjects affected / exposed	2 / 2062 (0.10%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	1 / 2	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Forearm fracture			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hand fracture			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	4 / 2062 (0.19%)	5 / 2049 (0.24%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			

subjects affected / exposed	6 / 2062 (0.29%)	9 / 2049 (0.44%)	
occurrences causally related to treatment / all	1 / 6	1 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint injury			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laceration			
subjects affected / exposed	2 / 2062 (0.10%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament rupture			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament sprain			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	2 / 2062 (0.10%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	1 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			

subjects affected / exposed	4 / 2062 (0.19%)	4 / 2049 (0.20%)	
occurrences causally related to treatment / all	1 / 4	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
subjects affected / exposed	4 / 2062 (0.19%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple fractures			
subjects affected / exposed	3 / 2062 (0.15%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	1 / 3	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle rupture			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle strain			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Overdose			
subjects affected / exposed	3 / 2062 (0.15%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patella fracture			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			
subjects affected / exposed	0 / 2062 (0.00%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 0	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax traumatic			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural complication			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural hypothyroidism			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative hernia			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound complication			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural pain			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pubis fracture			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary contusion			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiation pericarditis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiation pneumonitis			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiation skin injury			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			
subjects affected / exposed	7 / 2062 (0.34%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 7	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	1 / 2062 (0.05%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seroma			
subjects affected / exposed	4 / 2062 (0.19%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fracture			



subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue injury			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	2 / 2062 (0.10%)	6 / 2049 (0.29%)	
occurrences causally related to treatment / all	0 / 2	3 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic rupture			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sternal fracture			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	2 / 2062 (0.10%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haemorrhage			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic vertebral fracture			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	0 / 2062 (0.00%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheal injury			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulna fracture			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	5 / 2062 (0.24%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	1 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm			

subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			
subjects affected / exposed	3 / 2062 (0.15%)	6 / 2049 (0.29%)	
occurrences causally related to treatment / all	0 / 3	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Atrial septal defect			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syndactyly			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitello-intestinal duct remnant			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	4 / 2062 (0.19%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Adams-Stokes syndrome			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Angina pectoris			
subjects affected / exposed	8 / 2062 (0.39%)	8 / 2049 (0.39%)	
occurrences causally related to treatment / all	0 / 8	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			
subjects affected / exposed	2 / 2062 (0.10%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	2 / 2062 (0.10%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Atrial fibrillation			
subjects affected / exposed	15 / 2062 (0.73%)	19 / 2049 (0.93%)	
occurrences causally related to treatment / all	1 / 15	1 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block complete			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	4 / 2062 (0.19%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
Cardiac disorder			

subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	3 / 2062 (0.15%)	9 / 2049 (0.44%)	
occurrences causally related to treatment / all	0 / 3	0 / 11	
deaths causally related to treatment / all	0 / 1	0 / 4	
Cardiac failure acute			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure chronic			
subjects affected / exposed	0 / 2062 (0.00%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	4 / 2062 (0.19%)	9 / 2049 (0.44%)	
occurrences causally related to treatment / all	0 / 4	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac fibrillation			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac tamponade			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac valve disease			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			

subjects affected / exposed	2 / 2062 (0.10%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 0	
Cardiomyopathy			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiovascular insufficiency			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Conduction disorder			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congestive cardiomyopathy			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cor pulmonale			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Coronary artery disease			
subjects affected / exposed	2 / 2062 (0.10%)	7 / 2049 (0.34%)	
occurrences causally related to treatment / all	0 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrocardiac syndrome			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic cardiomyopathy			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular dysfunction			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular failure			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve disease			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve incompetence			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	4 / 2062 (0.19%)	5 / 2049 (0.24%)	
occurrences causally related to treatment / all	1 / 4	1 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
Myocardial ischaemia			
subjects affected / exposed	2 / 2062 (0.10%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palpitations			

subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Restrictive cardiomyopathy			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sick sinus syndrome			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress cardiomyopathy			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachyarrhythmia			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	0 / 2062 (0.00%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tricuspid valve incompetence			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular extrasystoles			



subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachycardia			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Amnesia			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ataxia			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Balance disorder			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery stenosis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carpal tunnel syndrome			
subjects affected / exposed	6 / 2062 (0.29%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	4 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral amyloid angiopathy			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cerebral infarction			
subjects affected / exposed	6 / 2062 (0.29%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	1 / 6	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral ischaemia			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	5 / 2062 (0.24%)	8 / 2049 (0.39%)	
occurrences causally related to treatment / all	0 / 5	3 / 9	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cervicobrachial syndrome			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Convulsion			
subjects affected / exposed	3 / 2062 (0.15%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia Alzheimer's type			

subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Dizziness			
subjects affected / exposed	6 / 2062 (0.29%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	1 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysarthria			
subjects affected / exposed	2 / 2062 (0.10%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalopathy			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paresis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Headache			
subjects affected / exposed	4 / 2062 (0.19%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	2 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic encephalopathy			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Horner's syndrome			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoaesthesia			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial aneurysm			
subjects affected / exposed	2 / 2062 (0.10%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypogeusia			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar radiculopathy			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Monoplegia			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple sclerosis			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple sclerosis relapse			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myasthenia gravis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Optic neuritis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parkinsonism			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Partial seizures			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Petit mal epilepsy			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sciatica			

subjects affected / exposed	2 / 2062 (0.10%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sensory loss			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Speech disorder			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal claudication			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal epidural haemorrhage			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	4 / 2062 (0.19%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 5	1 / 3	
deaths causally related to treatment / all	0 / 0	1 / 1	
Syncope			
subjects affected / exposed	4 / 2062 (0.19%)	13 / 2049 (0.63%)	
occurrences causally related to treatment / all	0 / 4	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tardive dyskinesia			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient global amnesia			

subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	5 / 2062 (0.24%)	8 / 2049 (0.39%)	
occurrences causally related to treatment / all	1 / 5	2 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tremor			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Trigeminal neuralgia			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIIth nerve paralysis			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebrobasilar insufficiency			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 2062 (0.15%)	4 / 2049 (0.20%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune haemolytic anaemia			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic anaemia			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Hearing impaired			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inner ear disorder			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tinnitus			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tympanic membrane perforation			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo			
subjects affected / exposed	1 / 2062 (0.05%)	8 / 2049 (0.39%)	
occurrences causally related to treatment / all	0 / 1	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo positional			



subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Cataract			
subjects affected / exposed	2 / 2062 (0.10%)	9 / 2049 (0.44%)	
occurrences causally related to treatment / all	0 / 2	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dacryostenosis acquired			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diplopia			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucoma			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lens dislocation			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular hole			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Open angle glaucoma			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal detachment			

subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vein thrombosis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vision blurred			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal adhesions			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal distension			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	5 / 2062 (0.24%)	9 / 2049 (0.44%)	
occurrences causally related to treatment / all	0 / 6	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain lower			
subjects affected / exposed	3 / 2062 (0.15%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			

subjects affected / exposed	7 / 2062 (0.34%)	6 / 2049 (0.29%)	
occurrences causally related to treatment / all	1 / 7	2 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wall haematoma			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal sphincter atony			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic			
subjects affected / exposed	2 / 2062 (0.10%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis microscopic			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ulcerative			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			

subjects affected / exposed	3 / 2062 (0.15%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crohn's disease			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	5 / 2062 (0.24%)	8 / 2049 (0.39%)	
occurrences causally related to treatment / all	2 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Duodenal ulcer			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspepsia			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocutaneous fistula			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterovesical fistula			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Faecal incontinence			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Faeces discoloured			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral hernia			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric polyps			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			

subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer haemorrhage			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer perforation			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	5 / 2062 (0.24%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	1 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis erosive			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorder			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	3 / 2062 (0.15%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			

subjects affected / exposed	3 / 2062 (0.15%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	2 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hiatus hernia			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	3 / 2062 (0.15%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus paralytic			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inflammatory bowel disease			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	2 / 2062 (0.10%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal dilatation			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	2 / 2062 (0.10%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal perforation			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal polyp			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			
subjects affected / exposed	2 / 2062 (0.10%)	7 / 2049 (0.34%)	
occurrences causally related to treatment / all	0 / 2	1 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mouth cyst			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	6 / 2062 (0.29%)	11 / 2049 (0.54%)	
occurrences causally related to treatment / all	1 / 6	2 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis			



subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	2 / 2062 (0.10%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	5 / 2062 (0.24%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	3 / 2062 (0.15%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spigelian hernia			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stomatitis			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth loss			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Volvulus			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	6 / 2062 (0.29%)	11 / 2049 (0.54%)	
occurrences causally related to treatment / all	0 / 6	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Biliary colic			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			
subjects affected / exposed	5 / 2062 (0.24%)	7 / 2049 (0.34%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis chronic			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			

subjects affected / exposed	11 / 2062 (0.53%)	8 / 2049 (0.39%)	
occurrences causally related to treatment / all	0 / 11	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestasis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder perforation			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder polyp			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cirrhosis			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic function abnormal			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic steatosis			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver disorder			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Alopecia			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermal cyst			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erythema multiforme			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erythrodermic psoriasis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertrophic scar			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Keloid scar			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pruritus			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash maculo-papular			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin lesion			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin necrosis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urticaria			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urticaria chronic			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Calculus bladder			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus ureteric			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urinary			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	3 / 2062 (0.15%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			

subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertonic bladder			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	2 / 2062 (0.10%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrotic syndrome			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyuria			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	7 / 2062 (0.34%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 0	
Renal failure acute			
subjects affected / exposed	2 / 2062 (0.10%)	6 / 2049 (0.29%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure chronic			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress urinary incontinence			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral caruncle			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral obstruction			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary incontinence			
subjects affected / exposed	4 / 2062 (0.19%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract obstruction			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Autoimmune thyroiditis			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Goitre			

subjects affected / exposed	2 / 2062 (0.10%)	4 / 2049 (0.20%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperparathyroidism			
subjects affected / exposed	3 / 2062 (0.15%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypothyroidism			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic nodular goitre			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	6 / 2062 (0.29%)	9 / 2049 (0.44%)	
occurrences causally related to treatment / all	5 / 6	3 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	9 / 2062 (0.44%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	2 / 10	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	10 / 2062 (0.48%)	6 / 2049 (0.29%)	
occurrences causally related to treatment / all	1 / 10	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone pain			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Compartment syndrome			



subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Costochondritis			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot deformity			
subjects affected / exposed	2 / 2062 (0.10%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	6 / 2062 (0.29%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint instability			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint stiffness			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kyphosis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loose body in joint			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			

subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle atrophy			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle spasms			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	4 / 2062 (0.19%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 4	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			
subjects affected / exposed	3 / 2062 (0.15%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal stiffness			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myalgia			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myopathy			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	15 / 2062 (0.73%)	21 / 2049 (1.02%)	
occurrences causally related to treatment / all	1 / 15	0 / 26	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteopenia			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporosis			
subjects affected / exposed	1 / 2062 (0.05%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	1 / 1	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyarthritis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudarthrosis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			
subjects affected / exposed	2 / 2062 (0.10%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column stenosis			
subjects affected / exposed	1 / 2062 (0.05%)	4 / 2049 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal osteoarthritis			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal pain			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylolisthesis			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovial cyst			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovitis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tenosynovitis			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Trigger finger			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	2 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess limb			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess neck			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess soft tissue			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			

subjects affected / exposed	5 / 2062 (0.24%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis perforated			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis bacterial			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis infective			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast abscess			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cellulitis			
subjects affected / exposed	4 / 2062 (0.19%)	6 / 2049 (0.29%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	4 / 2062 (0.19%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopneumonia			
subjects affected / exposed	2 / 2062 (0.10%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			

subjects affected / exposed	9 / 2062 (0.44%)	8 / 2049 (0.39%)	
occurrences causally related to treatment / all	0 / 10	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	3 / 2062 (0.15%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	3 / 2062 (0.15%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	7 / 2062 (0.34%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalitis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Erysipelas			
subjects affected / exposed	8 / 2062 (0.39%)	5 / 2049 (0.24%)	
occurrences causally related to treatment / all	0 / 9	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia sepsis			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder empyema			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	2 / 2062 (0.10%)	7 / 2049 (0.34%)	
occurrences causally related to treatment / all	0 / 2	1 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis Escherichia coli			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis norovirus			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Helicobacter infection			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	2 / 2062 (0.10%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site abscess			



subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected skin ulcer			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	3 / 2062 (0.15%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngitis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lobar pneumonia			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised infection			
subjects affected / exposed	1 / 2062 (0.05%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	4 / 2062 (0.19%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lymphangitis			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mastitis			
subjects affected / exposed	5 / 2062 (0.24%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nosocomial infection			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral candidiasis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periorbital cellulitis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			

subjects affected / exposed	2 / 2062 (0.10%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal abscess			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pilonidal cyst			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	29 / 2062 (1.41%)	16 / 2049 (0.78%)	
occurrences causally related to treatment / all	0 / 30	0 / 19	
deaths causally related to treatment / all	0 / 1	0 / 1	
Pneumonia klebsiella			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia legionella			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural cellulitis			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural pneumonia			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			

subjects affected / exposed	2 / 2062 (0.10%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudomembranous colitis			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudomonas bronchitis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	2 / 2062 (0.10%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyometra			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	3 / 2062 (0.15%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	8 / 2062 (0.39%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 8	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			

subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Skin infection			
subjects affected / exposed	3 / 2062 (0.15%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue infection			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	8 / 2062 (0.39%)	7 / 2049 (0.34%)	
occurrences causally related to treatment / all	1 / 9	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 0	
Urosepsis			
subjects affected / exposed	3 / 2062 (0.15%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal infection			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular neuronitis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral diarrhoea			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulvitis			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	1 / 2062 (0.05%)	3 / 2049 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	1 / 2062 (0.05%)	7 / 2049 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			

subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid overload			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	2 / 2062 (0.10%)	4 / 2049 (0.20%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	0 / 2062 (0.00%)	2 / 2049 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 2062 (0.00%)	4 / 2049 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypophagia			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemia			
subjects affected / exposed	1 / 2062 (0.05%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obesity			

subjects affected / exposed	0 / 2062 (0.00%)	1 / 2049 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 2062 (0.05%)	0 / 2049 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Anastrozole	Letrozole	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1762 / 2062 (85.45%)	1747 / 2049 (85.26%)	
Injury, poisoning and procedural complications			
Radiation skin injury			
subjects affected / exposed	88 / 2062 (4.27%)	120 / 2049 (5.86%)	
occurrences (all)	88	121	
Vascular disorders			
Hot flush			
subjects affected / exposed	666 / 2062 (32.30%)	666 / 2049 (32.50%)	
occurrences (all)	714	702	
Hypertension			
subjects affected / exposed	145 / 2062 (7.03%)	152 / 2049 (7.42%)	
occurrences (all)	148	152	
Lymphoedema			
subjects affected / exposed	177 / 2062 (8.58%)	158 / 2049 (7.71%)	
occurrences (all)	182	165	
Nervous system disorders			
Dizziness			
subjects affected / exposed	107 / 2062 (5.19%)	92 / 2049 (4.49%)	
occurrences (all)	116	99	
Headache			
subjects affected / exposed	164 / 2062 (7.95%)	127 / 2049 (6.20%)	
occurrences (all)	184	134	
General disorders and administration			



site conditions			
Fatigue			
subjects affected / exposed	341 / 2062 (16.54%)	345 / 2049 (16.84%)	
occurrences (all)	362	368	
Oedema peripheral			
subjects affected / exposed	104 / 2062 (5.04%)	100 / 2049 (4.88%)	
occurrences (all)	109	106	
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	148 / 2062 (7.18%)	127 / 2049 (6.20%)	
occurrences (all)	162	139	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	120 / 2062 (5.82%)	106 / 2049 (5.17%)	
occurrences (all)	122	115	
Dyspnoea			
subjects affected / exposed	92 / 2062 (4.46%)	111 / 2049 (5.42%)	
occurrences (all)	94	121	
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	134 / 2062 (6.50%)	126 / 2049 (6.15%)	
occurrences (all)	137	131	
Psychiatric disorders			
Depression			
subjects affected / exposed	129 / 2062 (6.26%)	141 / 2049 (6.88%)	
occurrences (all)	133	144	
Insomnia			
subjects affected / exposed	149 / 2062 (7.23%)	160 / 2049 (7.81%)	
occurrences (all)	154	165	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	983 / 2062 (47.67%)	983 / 2049 (47.97%)	
occurrences (all)	1192	1181	
Back pain			
subjects affected / exposed	187 / 2062 (9.07%)	207 / 2049 (10.10%)	
occurrences (all)	199	229	

Bone pain			
subjects affected / exposed	120 / 2062 (5.82%)	138 / 2049 (6.73%)	
occurrences (all)	127	143	
Musculoskeletal pain			
subjects affected / exposed	144 / 2062 (6.98%)	122 / 2049 (5.95%)	
occurrences (all)	156	129	
Myalgia			
subjects affected / exposed	211 / 2062 (10.23%)	232 / 2049 (11.32%)	
occurrences (all)	223	254	
Osteopenia			
subjects affected / exposed	172 / 2062 (8.34%)	202 / 2049 (9.86%)	
occurrences (all)	172	203	
Osteoporosis			
subjects affected / exposed	224 / 2062 (10.86%)	221 / 2049 (10.79%)	
occurrences (all)	225	223	
Pain in extremity			
subjects affected / exposed	174 / 2062 (8.44%)	167 / 2049 (8.15%)	
occurrences (all)	193	191	
Metabolism and nutrition disorders			
Hypercholesterolaemia			
subjects affected / exposed	151 / 2062 (7.32%)	155 / 2049 (7.56%)	
occurrences (all)	151	160	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
26 January 2006	The protocol was updated to reflect the 2005 St Gallen's Early Breast Cancer consensus guidelines and the 2004 ASCO guidelines for the use of aromatase inhibitors for the adjuvant treatment of breast cancer and the use of bisphosphonates (Goldhirsch et al 2005, Winer et al Also, the steering committee recommended clear guidelines for different parties involved in the conduct of the trial including an independent group to control the analysis since the medication was not blinded.
19 September 2006	The protocol was amended to incorporate participating investigators' feedback after enrolling their initial patients to the study. They suggested the protocol be consistent with its approach of using standard institutional practices rather than a mix of pre-specified examinations and standard care since there was extensive experience with both of these agents in terms of safety. Both agents received approval for this indication by multiple health authorities around the world. Also, the steering committee reconsidered the inclusion of patients who had received neo-adjuvant chemotherapy and revised the treatment guidelines for patients with hyperlipidemia. The secondary objectives were updated to include distant disease-free survival with appropriate statistical methodology added to include this in the statistical plan.
10 May 2007	This amendment provided additional details concerning the central review of hormone receptors and HER2 status and added the central confirmation as a secondary objective for the study. Central confirmation of ER, PgR, and HER2 were mandatory for centers except where prohibited by regulations. Centers were asked to reconsent patients who had already been enrolled prior to the approval of amendment 3, if needed in order to ship their tumor blocks for central confirmation. Breast cancer researchers in general, strongly encouraged sites and patients to participate in studies which would further aid in the understanding and the complexity of this disease. The goal was to better understand which predictors defined the course of each breast cancer patient's disease. This was done by conducting correlative science studies. These studies were done in a subset of patients. Immunohistochemical analyses, tumor RNA profiling, tissue microarray analysis, estradiol, estrone and estrone sulfate levels, pharmacogenetics and proteomics comprised these studies. This amendment also updated the protocol information concerning statistical analysis of patients who had received neo-adjuvant therapy prior to study entry. The approval of amendment 2 allowed for the entry of these patients. New information regarding European Union regulatory guidelines and the lack of theoretical justification for the use of traditional statistical analyses in conjunction with a complex dynamic allocation became known after the approval of amendment 2.

25 March 2008	Amendment 4 updated the procedures for the handling of the biological samples and the addition of an evaluation of disease status at Month 18. The steering committee added additional endocrine and proteomics sampling times to allow more flexibility for the sites and patients. Month 6, 18, or 24 were options. A maximum of two samples were required but when the samples were obtained was flexible. Since the exact timing of the pharmacogenetic sample was not critical, the steering committee broadened the time when the sample could be obtained. It could be obtained at either baseline, month 6, 12, 18, or 24. The secondary objectives were updated to remove breast cancer specific survival since the current data collection forms did not specifically collect this information. Without the specific information collected, this endpoint could not be determined. Also, eliminated was the need to stratify by presence or absence of neo-adjuvant chemotherapy in the statistical analysis plan. Neo-adjuvant chemotherapy was not a stratification factor for the determination of the treatment assignment. There were very few patients in this category so this was of minimal interest. The formal process for handling protocol violations was added to the Procedures section of the protocol. Amendment 4 called for the completion of the study at 959 disease free survival (DFS) events and 5 years after the completion of enrollment. The event rate was lower than initially planned in the protocol, and the protocol was amended to extend the follow up period in order to continue the collection of the primary endpoint data. The study's second interim analysis was conducted after the data cutoff of 21-Nov-2013. It was based on 704 DFS events.
19 December 2013	Amendment 5 was created to extend the follow up period to continue to collect events/endpoints. Amendment 5 was released to the countries and sites in January 2014. It was approved by several of the countries, but none of the patients were re-consented. Based on the Kaplan-Meier curve from the second interim analysis, the statistical team modeled that it would take until 2022 to reach the 959 DFS events, the trial's primary endpoint. Considering that only approximately 1000 patients globally would be available for re-consenting and follow-up, the decision was made not to implement protocol amendment 5, which extended the follow-up period, and therefore terminate the trial early. Amendment 5 had been released, submitted, and approved in several countries and the global and local processes for early termination of the trial were implemented. No patients were re-consented nor were active participants in the extended follow-up period as part of Amendment 5.

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please use <https://www.novctrd.com/CtrdWeb/home.novfor> complete trial results.

Notes: